Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 1196305
Author(s) Ruiz, Christian; Holz, David R; Oeggerli, Martin; Schneider, Sandra; Gonzales, Irma M; Kiefer, Jeffrey M; Zellweger, Tobias; Bachmann, Alexander; Koivisto, Pasi A; Helin, Heikki J; Mousses, Spyro; Barrett, Michael T; Azorsa, David O; Bubendorf, Lukas
Author(s) at UniBasel Bachmann, Alexander
Bubendorf, Lukas
Zellweger, Tobias
Year 2011
Title Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer
Journal The journal of pathology
Volume 223
Number 4
Pages / Article-Number 543-52
Keywords vinculin, 10q22, array-CGH, prostate cancer, tissue microarray
Abstract Androgen withdrawal is the standard treatment for advanced prostate cancer. Although this therapy is initially effective, nearly all prostate cancers become refractory to it. Approximately 15% of these castration-resistant prostate cancers harbour a genomic amplification at 10q22. The aim of this study was to explore the structure of the 10q22 amplicon and to determine the major driving genes. Application of high-resolution array-CGH using the 244k Agilent microarrays to cell lines with 10q22 amplification allowed us to narrow down the common amplified region to a region of 5.8 megabases. We silenced each of the genes of this region by an RNAi screen in the prostate cancer cell lines PC-3 and 22Rv1. We selected genes with a significant growth reduction in the 10q22 amplified cell line PC-3, but not in the non-amplified 22Rv1 cells, as putative target genes of this amplicon. Immunohistochemical analysis of the protein expression of these candidate genes on a tissue microarray enriched for 10q22 amplified prostate cancers revealed vinculin as the most promising target of this amplicon. We found a strong association between vinculin gene amplification and overexpression (p < 0.001). Further analysis of 443 specimens from across all stages of prostate cancer progression showed that vinculin expression was highest in castration-resistant prostate cancers, but negative or very low in benign prostatic hyperplasia (p < 0.0001). Additionally, high tumour cell proliferation measured by Ki67 expression was significantly associated with high vinculin expression in prostate cancer (p < 0.0001). Our data suggest that vinculin is a major driving gene of the 10q22 amplification in prostate cancer and that vinculin overexpression might contribute to prostate cancer progression by enhancing tumour cell proliferation.
Publisher Wiley
ISSN/ISBN 0022-3417
edoc-URL http://edoc.unibas.ch/dok/A6006476
Full Text on edoc No
Digital Object Identifier DOI 10.1002/path.2828
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/21294127
ISI-Number WOS:000287672100010
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.443 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
10/08/2020